SCHEMBL4698022

SCHEMBL4698022

CCN(CC)CCn1ncc2c(Nc3cc(C(=O)Nc4cccc(C(F)(F)F)c4)ccc3C)nc(Cl)nc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 10/20 0.59
LCK P06239 6/20 0.59
SRC P12931 4/20 0.59
MAPK14 Q16539 4/20 0.59
EPHB2 P29323 3/20 0.59
DDR1 Q08345 3/20 0.59
DDR2 Q16832 3/20 0.59
INSR P06213 3/20 0.59
LYN P07948 3/20 0.59
HCK P08631 3/20 0.59
KDR P35968 3/20 0.59
ESYT2 A0FGR8 2/20 0.59
NBAS A2RRP1 2/20 0.59
CNOT1 A5YKK6 2/20 0.59
TBKBP1 A7MCY6 2/20 0.59
AGPS O00116 2/20 0.59
MYO1F O00160 2/20 0.59
SNAP23 O00161 2/20 0.59
AP3B1 O00203 2/20 0.59
PSMD12 O00232 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4696804 0.91 BRAF (0.62) BRAFLCKSRCMAPK14EPHB2
SCHEMBL4919390 0.89 BRAF (0.61) BRAFLCKSRCMAPK14EPHB2
SCHEMBL4697113 0.89 POLB (0.59) BRAFLCKSRCMAPK14EPHB2
SCHEMBL4916509 0.88 ABL1 (0.78) BRAFLCKSRCMAPK14EPHB2
SCHEMBL4697130 0.86 BRAF (0.61) BRAFLCKSRCMAPK14EPHB2
SCHEMBL4697939 0.84 BRAF (0.54) BRAFLCKSRCMAPK14EPHB2
SCHEMBL4699063 0.83 BRAF (0.55) BRAFLCKSRCINSRLYN
SCHEMBL4697700 0.81 BRAF (0.63) BRAFLCKSRCMAPK14EPHB2
SCHEMBL4922941 0.81 ABL1 (0.80) BRAFLCKSRCMAPK14EPHB2
SCHEMBL20558364 0.79 BRAF (0.64) BRAFLCKSRCMAPK14EPHB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors HOLZER PHILIPP 2008-11-06 US disclosed
EP-1963327-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007062805-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS NOVARTIS AG (CH) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors EPHB3, EPHB2, EPHB1 BRAF 42/4885LCK 35/4885SRC 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.